Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-103: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs ODM 103 (Primary) ; Entacapone; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacodynamics
- Acronyms NOCOS
- Sponsors Orion Pharma
- 18 Sep 2014 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
- 01 Nov 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 08 Aug 2013 Planned end date changed from 1 Sep 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.